REHOVOT, Israel, March 19,
2024 /PRNewswire/ -- Lavie
Bio Ltd., a leading ag-biologicals company that
develops microbiome-based, computational-driven bio-stimulant and
bio-pesticide novel products and a subsidiary of Evogene Ltd.
(Nasdaq: EVGN) (TASE: EVGN), announced today that it is extending
its joint validation trials for its biofungicides conducted by
Bayer AG, a global leader in the agriculture
industry, after successful first-year laboratory and
greenhouse testing. The tests have demonstrated the efficacy of
Lavie Bio's biofungicides in
addressing devastating diseases that affect fruits and vegetables
worldwide. Building on these positive outcomes, the companies are
progressing to a second year of validation trials in field
experiments.
"This is an important step in our open innovation strategy to
bring new biological solutions to growers," said Benoit Hartmann, Head of Biologics at Bayer Crop
Science. "Biofungicides are a real opportunity for innovation,
and we are looking forward to the new solutions this partnership
with Lavie Bio helps us deliver
together."
"We are delighted with the consistently positive results we have
observed in our experiments, which has led to the decision to
extend the validation trials for another year in the field," said
Amit Noam, CEO of Lavie Bio. "This not only highlights the
immense business potential of our product and its meaningful impact
on farmers worldwide but also reinforces our dedication to
collaborative partnerships within the industry as we work together
to deliver innovative solutions to the market."
The emergence of innovative ag biologicals, particularly
biofungicides, provides a sustainable and responsible approach to
disease management at a time when farmers are left with limited
options to effectively address diseases that can pose a major
threat to crop yield. These products demonstrate high efficacy in
controlling oomycetes while minimizing environmental impact,
thereby promoting sustainable agricultural practices.
Lavie Bio's commitment to
refining its promising bio fungicides through joint validation
trials with Bayer AG serves as a powerful testament to the
company's development capabilities, leveraging its innovative BDD
platform powered by Evogene's MicroBoost AI tech-engine.
About Lavie Bio Ltd.:
Lavie Bio, a subsidiary of
Evogene Ltd., aims to improve food quality, sustainability, and
agriculture productivity through the introduction of
microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational
predictive platform, the BDD platform, powered by Evogene's
proprietary MicroBoost AI tech-engine, harnessing the power
of big data, artificial intelligence, and advanced informatics, for
the discovery, optimization and development of bio-stimulant and
bio-pesticide products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd.
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
probability of success while reducing development time and cost.
Evogene established three unique technological engines -
MicroBoost AI, ChemPass AI and GeneRator
AI – leveraging Big Data and Artificial Intelligence and
incorporating deep multidisciplinary understanding in life
sciences. Each technological engine is focused on the discovery and
development of products based on one of the following core
components: microbes (MicroBoost AI), small molecules
(ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its technological engines to develop products through
subsidiaries and with strategic partners. Currently, Evogene's main
subsidiaries utilize the technological engines to develop human
microbiome-based therapeutics by Biomica Ltd., medical cannabis
products by Canonic Ltd., ag-chemicals by AgPlenus Ltd. and
ag-biologicals by Lavie Bio Ltd. For more information, please
visit: www.evogene.com
Investor Relations Contact
Rachel Pomerantz Gerber I Head of
Investor Relations at Evogene
rachel.pomerantz@evogene.com I Tel: +972-8-9311901
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates" or words of similar
meaning. For example, Lavie Bio and
Evogene are using forward-looking statements in this press release
when they discuss the efficacy of Lavie
Bio's biofungicides in addressing diseases, the ability of
Lavie Bio and Bayer to bring new
biological solutions to growers, future results of the trials
conducted by Lavie Bio and Bayer.
Such statements are based on current expectations, estimates,
projections, and assumptions, describe opinions about future
events, involve certain risks and uncertainties which are difficult
to predict and are not guarantees of future performance. Therefore,
actual future results, performance, or achievements of Evogene and
its subsidiaries may differ materially from what is expressed or
implied by such forward-looking statements due to a variety of
factors, many of which are beyond the control of Evogene and its
subsidiaries, including, without limitation, the
current war between Israel and
Hamas and any worsening of the situation in Israel such as further mobilizations or
escalation in the northern border of Israel, and those risk factors
contained in Evogene's reports filed with the applicable securities
authorities. In addition, Evogene and its subsidiaries rely,
and expect to continue to rely, on third parties to conduct certain
activities, such as their field-trials and pre-clinical studies,
and if these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet
expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities.
Evogene and its subsidiaries disclaim any obligation or
commitment to update these forward-looking statements to reflect
future events or developments or changes in expectations,
estimates, projections.
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo -
https://mma.prnewswire.com/media/945133/lavie_bio_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/bayer-ag-and-lavie-bio-continue-for-second-year-of-biofungicides-validation-following-successful-lab-and-greenhouse-testing-302092865.html
SOURCE Lavie Bio